Abstract
Background: Abnormal glycosylation of proteins has been identified in almost all types of cancers and is closely related to the cancer progression, metastasis, and survival of cancer patients. This study was to explore the values of serum tumor abnormal protein (TAP), an abnormal glycochain protein, in the diagnosis and prognosis of gastric cancer (GC). Methods: A total of 335 GC patients were included as the study group, and another 335 subjects served as the control group. Tumor abnormal protein expression was compared between the 2 groups. Correlation analysis was used to assess the correlations of TAP with clinicopathological factors. Gastric cancer patients were divided into training set and test set at a ratio of 2:1. Univariate and multivariate Cox regression analyses in training set were used to evaluate the prognostic significance of TAP in GC patients and explore the independent risk factors for overall survival (OS) and disease-free survival (DFS) to establish a prognostic model, followed by testing of the model. According to the median of TAP, 335 GC patients were divided into 2 groups to plot the survival curves of OS and DFS. Results: Tumor abnormal protein expression in the study group was significantly higher than in the control group. Taking the best cut-off value of TAP (110.128 μm2) as the diagnostic criteria for GC, the sensitivity and specificity of TAP were 83.58% and 97.61%, respectively, and the area under the receiver operating characteristics (ROC) curve was 0.935, which was not inferior to computed tomography (CT). Tumor abnormal protein expression was an independent risk factor for OS and DFS. The prognostic predictive value of TAP was better than that of pathological stage in GC patients. The model with TAP was effective in predicting prognosis. Conclusion: Tumor abnormal protein is an effective indicator for early screening and prognostic evaluation of GC and can also assist the clinical diagnosis and treatment of GC.
Funding Information
  • Science and Technology Innovation Project of Suzhou Medical and Health Care (SKJY2021114)
  • Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Science and Technology Innovation
  • Science and Technology Development Fund of Nanjing Medical University (NMUB2020268)
  • National Natural Science Foundation of China (81871946)
  • National Natural Science Foundation of China (82072708)
  • Primary Research & Development Plan of Jiangsu Province (BE2016786)
  • Jiangsu Key Medical Discipline (ZDXKA2016005)
  • Special Foundation for National Science and Technology Basic Research Program of China (2019FY101104)
  • Program for Development of Innovative Research Team in the First Hospital of Nanjing Medical University
  • Priority Academic Program Development of Jiangsu Higher Education Institutions (JX10231801)
  • Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment

This publication has 41 references indexed in Scilit: